Investment in Talent and R&D to Develop and Expand Services
First written in FY2022-Q3. 6 of 12 entries say "Restated". Latest entry: 2026-08-12.
38 other companies' latest entry also says "Advanced".
- 2026-08-12AdvancedEarnings presentation
「Research and development to optimize LLM costs」
The company specified investment in research and development to optimize LLM costs at Exa Interaction Design Lab. - FY2026AdvancedAnnual report
「Total research and development expenses recorded during the consolidated fiscal year were ¥391 million, including ¥81 million recorded by the corporate division.」
Research and development expenses increased from ¥178 million in the previous fiscal year to ¥391 million, and the company expanded its research and development investments in AI products, medical and healthcare, SalesTech and other areas. - FY2026-H1RestatedAnnual report
「The group's total research and development expenses for the interim consolidated accounting period were ¥212 million. There were no material changes in the status of the group's research and development activities during the interim consolidated accounting period.」
The company recorded ¥212 million in research and development expenses and stated that there were no material changes in the status of research and development activities. - FY2025AdvancedAnnual report
「Total capital expenditures during the consolidated fiscal year were ¥994 million, mainly relating to product development.」
The company recorded ¥994 million in capital expenditures, mainly for product development, and ¥178 million in research and development expenses, continuing its development and research investments. - FY2024-Q3RestatedAnnual report
「The group's total research and development expenses for the nine months ended the third quarter were ¥105 million. There were no material changes in the status of the group's research and development activities during the nine months ended the third quarter.」
Research and development expenses for the nine months ended the third quarter were ¥105 million, and it is stated that there were no material changes in the status of research and development activities. - FY2024-Q2RestatedAnnual report
「The group's total research and development expenses for the six months ended the second quarter were ¥69 million. There were no material changes in the status of the group's research and development activities during the six months ended the second quarter.」
Research and development expenses for the six months ended the second quarter were ¥69 million, and it is stated that there were no material changes in research and development activities. - FY2024-Q1RestatedAnnual report
「The group's total research and development expenses for the three months ended the first quarter were ¥36 million. There were no material changes in the status of the group's research and development activities during the three months ended the first quarter.」
Research and development expenses for the first quarter were ¥36 million, and it is stated that there were no material changes in research and development activities. - FY2023AdvancedAnnual report
「Total capital expenditures during the consolidated fiscal year were ¥923 million, mainly relating to product development costs and other expenses.」
The company recorded annual capital expenditures of ¥923 million, ¥845 million in purchases of intangible fixed assets, and ¥75 million in research and development expenses, and described investments in exaBase DX Assessment & Learning, CareWiz Hanasto, exaBase robotics, exaBase Studio and other products. - FY2023-Q3RestatedAnnual report
「The group's total research and development expenses for the nine months ended the third quarter were ¥60 million. There were no material changes in the status of the group's research and development activities during the nine months ended the third quarter.」
Research and development expenses for the nine months ended the third quarter were ¥60 million, and it is stated that there were no material changes in the status of research and development activities. - FY2023-Q2RestatedAnnual report
「The main working capital requirements of our group are software investments related to product development to develop and expand our services, recruitment costs for AI consultants, engineers and other personnel to drive business growth, and personnel costs associated with increasing headcount.」
The company reiterates software investments for new service development and expansion, recruitment costs for AI personnel, and personnel costs associated with increasing headcount as its main funding requirements. - FY2022AdvancedAnnual report
「Total research and development expenses recorded during the consolidated fiscal year were ¥301.456 million, including ¥49.796 million recorded by the corporate division.」
Research and development expenses increased to ¥301.456 million, with the AI Platform Business conducting R&D mainly in Robot Tech, medical and healthcare, and image processing. - FY2022-Q3First statedAnnual report
「The main working capital requirements of our group are personnel costs for development staff to develop and expand our services, and advertising and promotional expenses to acquire customers.」
The main working capital requirements are development personnel costs for new development and service expansion, and customer acquisition costs. Research and development expenses are stated at ¥241.170 million.